M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers BioPharma DiveEquipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.M&A / DealsImmunology & InflammationRead full story pharminent April 15, 2026 (Last updated: April 16, 2026) BioPharma Dive Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases. M&A / DealsImmunology & InflammationRead full story Post navigation Previous: Travere wins long-awaited approval for kidney disease drugNext: Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
